Multifunctional Sodium Hyaluronate/Chitosan Foam Used as an Absorbable Hemostatic Material

• Published in: Bioengineering (Basel) Vol. 10; no. 7; p. 868
• Main Authors: Chen, Ran, Du, Fanglin, Yuan, Qipeng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Adhesion; Adsorption; Animal models; Biocompatibility; biodegradable; Bioengineering; Bleeding; Blood cells; carboxymethyl chitosan; Cellulose; Chitosan; Coagulation; composite material; Composite materials; Contact angle; Degradation; Hemostasis; hemostatic foam; Hemostatics; hyaluronic acid; Hydrogen bonding; Injuries; Liver; Metabolism; Polysaccharides; Properties; Scanning electron microscopy; Sodium; Sodium hyaluronate; Spectrum analysis; Wound healing; China; United States > US; biodegradable; composite material; carboxymethyl chitosan; hemostatic foam; hyaluronic acid
• ISSN: 2306-5354; 2306-5354
• DOI: 10.3390/bioengineering10070868

Absorbable hemostatic materials have great potential in clinical hemostasis. However, their single coagulation mechanism, long degradation cycles, and limited functionality mean that they have restricted applications. Here, we prepared a sodium hyaluronate/carboxymethyl chitosan absorbable hemostatic foam (SHCF) by combining high-molecular-weight polysaccharide sodium hyaluronate with carboxymethyl chitosan via hydrogen bonding. SHCFs have rapid liquid absorption performance and can enrich blood cells. They transform into a gel when it they come into contact with blood, and are more easily degraded in this state. Meanwhile, SHCFs have multiple coagulation effects and promote hemostasis. In a rabbit liver bleeding model, SHCFs reduced the hemostatic time by 85% and blood loss by 80%. In three severe and complex bleeding models of porcine liver injury, uterine wall injury, and bone injury, bleeding was well-controlled and anti-tissue adhesion effects were observed. In addition, degradation metabolism studies show that SHCFs are 93% degraded within one day and almost completely metabolized within three weeks. The absorbable hemostatic foam developed in this study is multifunctional; with rapid hemostasis, anti-adhesion, and rapid degradation properties, it has great clinical potential for in vivo hemostasis.